中性粒细胞/淋巴细胞比值联合可溶性生长刺激表达基因2蛋白对中重度急性一氧化碳中毒心肌损伤患者院内主要不良心血管事件的预测价值:单中心前瞻性观察研究
该单中心前瞻性观察研究纳入2016年11月至2020年2月河北医科大学附属哈励逊国际和平医院急诊科278例中重度急性一氧化碳中毒心肌损伤患者,院内MACE发生率为11.51%(32/278)。MACE组cTnI、乳酸、NLR及入院3天sST2均显著高于非MACE组(P<0.05),而入院时sST2两组无显著差异(P>0.05)。二元Logistic回归显示T3 d sST2(OR 1.064,95%CI 1.039-1.090,P<0.01)和NLR(OR 1.176,95%CI 1.066-1.298,P<0.01)均为院内MACE独立危险因素。NLR联合T3 d sST2预测MACE的AUC为0.876,优于单一NLR(AUC 0.754)和T3 d sST2(AUC 0.813)。
要点
- 中重度ACOP心肌损伤患者院内MACE发生率为11.51%(32/278),MACE组NLR 13.14±4.37 vs 非MACE组9.49±4.21(P<0.05)。
- 入院3天sST2为独立危险因素:OR 1.064(95%CI 1.039-1.090),P<0.01;NLR OR 1.176(95%CI 1.066-1.298),P<0.01。
- NLR预测MACE最佳临界值10.02,敏感度69.8%、特异度74.3%;T3 d sST2最佳临界值43.50 μg/L,敏感度86.2%、特异度70.4%。
- NLR联合T3 d sST2预测AUC 0.876,优于单一NLR(0.754)和T3 d sST2(0.813),联合检测敏感度79.8%、特异度83.4%。
- 入院时sST2在MACE组与非MACE组无显著差异(269.09±90.89 vs 240.14±113.02 μg/L,P>0.05)。
适用人群与场景
- 2016年11月至2020年2月河北医科大学附属哈励逊国际和平医院急诊科收治的中重度急性一氧化碳中毒合并心肌损伤患者,最终分析278例。
诊断标准与关键阈值
- 以NLR最佳临界值10.02和T3 d sST2最佳临界值43.50 μg/L预测中重度ACOP心肌损伤患者院内MACE,NLR>10.02且T3 d sST2>43.50 μg/L时应警惕MACE发生。
红旗征与不能漏的情况
- 中重度ACOP心肌损伤患者NLR>10.02且入院3天sST2>43.50 μg/L时,应警惕院内主要不良心血管事件发生。
研究设计与关键结果
- 单中心前瞻性观察研究纳入278例中重度ACOP心肌损伤患者,院内MACE发生率为11.51%(32/278)。
- MACE组cTnI(μg/L)0.83±0.15 vs 非MACE组0.46±0.37,乳酸(mmol/L)2.96±1.14 vs 2.43±1.35,NLR 13.14±4.37 vs 9.49±4.21,T3 d sST2(μg/L)59.88±23.42 vs 39.83±12.60,均P<0.05。
- 入院时sST2(T0 sST2,μg/L)MACE组269.09±90.89 vs 非MACE组240.14±113.02,P>0.05,两组无显著差异。
- Pearson相关分析:NLR与APACHE II评分、T3 d sST2与APACHE II评分、NLR与T3 d sST2均呈显著正相关(r值分别为0.226、0.209、0.193,均P<0.01)。
- 二元Logistic回归:T3 d sST2(OR 1.064,95%CI 1.039-1.090,P<0.01)和NLR(OR 1.176,95%CI 1.066-1.298,P<0.01)均为院内MACE独立危险因素。
- ROC曲线:NLR联合T3 d sST2预测院内MACE的AUC为0.876,优于NLR(AUC 0.754)和T3 d sST2(AUC 0.813)。
- NLR最佳临界值10.02时预测MACE敏感度69.8%、特异度74.3%;T3 d sST2最佳临界值43.50 μg/L时敏感度86.2%、特异度70.4%;联合检测敏感度79.8%、特异度83.4%。
证据类型、等级与局限
- 证据类型:单中心前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NLR和T3 d sST2是中重度ACOP心肌损伤患者院内MACE的独立预测因子,联合应用具有良好预测价值;对于NLR>10.02且T3 d sST2>43.50 μg/L的患者,应警惕院内MACE发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the predictive neutrophil/lymphocyte ratio (NLR) combined with soluble growth stimulating expression gene 2 protein (sST2) on in-hospital major adverse cardiovascular events (MACE) in patients with myocardial injury following moderate-severe acute carbon monoxide poisoning (ACOP).
METHODS: A single-cente prospective observational approach was conducted. Moderate-severe ACOP patients with myocardial damage from November 2016 to February 2020 in department of emergency medicine of Harrison International Peace Hospital Affiliated to Hebei Medical University were enrolled. The baseline data of the patients, NLR and sST2 (T0 sST2) on admission, sST2 at 3 days after admission (T3 d sST2), and the other myocardial injury and biochemical indicators were collected. According to whether MACE occurred, the patients were divided into MACE group and non-MACE group. The clinical data of the two groups were compared. Pearson correlation analysis was used to analyze the correlation of each index. Binary Logistic regression was used to analyze the independent risk factors of in-hospital MACE in patients with moderate-severe ACOP myocardial injury. The receiver operator characteristic curve (ROC curve) was drawn and area under ROC curve (AUC) was calculated to analyze the predictive value of NLR, sST2, and NLR combined with sST2 for the occurrence of in-hospital MACE in patients with moderate-severe ACOP myocardial injury.
RESULTS: A total of 278 patients with moderate-severe ACOP myocardial injury were included in the final analysis, and the incidence of MACE was 11.51% (32/278). Cardiac troponin I (cTnI), lactic acid (Lac), NLR, and T3 d sST2 in the MACE group were significantly higher than those in the non-MACE group [cTnI (μg/L): 0.83±0.15 vs. 0.46±0.37, Lac (mmol/L): 2.96±1.14 vs. 2.43±1.35, NLR: 13.14±4.37 vs. 9.49±4.21, T3 d sST2 (μg/L): 59.88±23.42 vs. 39.83±12.60, all P < 0.05], there was no significant difference in T0 sST2 between the MACE group and the non-MACE group (μg/L: 269.09±90.89 vs. 240.14±113.02, P > 0.05). Pearson correlation analysis showed that there were significantly positive correlations in NLR with acute physiology and chronic health evaluation II (APACHE II), T3 d sST2 with APACHE II, and NLR with T3 d sST2 (r values were 0.226, 0.209, 0.193, all P < 0.01). Binary Logistic regression analysis showed that T3 d sST2 and NLR were both independent risk factors for MACE in moderate-severe ACOP patients with myocardial injury [odds ratio (OR) and 95% confidence interval (95%CI) respectively was 1.064 (1.039-1.090), 1.176 (1.066-1.298), both P < 0.01]. ROC curve analysis showed that the predictive efficacy of NLR combined with T3 d sST2 for the occurrence of in-hospital MACE in patients with ACOP myocardial injury (AUC = 0.876) was better than that of NLR (AUC = 0.754) and T3 d sST2 (AUC = 0.813). When the optimal critical value of NLR was 10.02 and that of T3 d sST2 was 43.50 μg/L, the sensitivity of predicting the occurrence of MACE in patients with moderate-severe ACOP myocardial injury was 69.8% and 86.2% respectively, and the specificity was 74.3% and 70.4%, respectively. The specificity and sensitivity of the combined detection was 83.4% and 79.8%, respectively.
CONCLUSIONS: NLR and T3 d sST2 were independent predictors of in-hospital MACE in moderate-severe ACOP patients with myocardial injury, and combined application of NLR and T3 d sST2 had good predictive value. For patients with moderate-severe ACOP myocardial injury with NLR > 10.02 and T3 d sST2 > 43.50 μg/L, the occurrence of in-hospital MACE should be alert.
参考来源
- Liu Q, Xiao Q, Han Y, et al. [Predictive value of neutrophil/lymphocyte ratio combined with soluble growth stimulating expression gene 2 protein on the occurrence of in-hospital major adverse cardiaovascular events in patients with myocardial injury from moderate-severe acute carbon monoxide poisoning: a single-center prospective observational study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34839867. doi:10.3760/cma.j.cn121430-20210410-00273
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。